News

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...
Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...
Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...
One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a popular platform reveals the hidden risks of online prescriptions.
Via its past collaborations with Novo Nordisk and Sanofi, two medicines made using its capabilities have been commercialized, one of which targets GLP-1.In the first half of 2024, it brought in ...
GLP-1 medicines for weight-loss are undoubtedly a secular growth story, and Novo Nordisk has been a wonderful investment over the past several years as a result.
Novo Nordisk accounts for 34% of the global diabetes market, including roughly half of both the $15 billion insulin therapy market and the nearly $40 billion GLP-1 market.
Ozempic, a GLP-1 agonist approved for managing type 2 diabetes, is Novo Nordisk’s top-selling product, accounting for 65.6 billion Danish krone (about $9.4 billion) in 2023 sales through the ...
Pharmaceutical company Novo Nordisk is teaming up with direct-to-consumer telehealth company Hims & Hers to offer discounted access to Wegovy, a GLP-1 manufactured by Novo Nordisk, the companies ...
Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...
Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide (GLP-1 RA)-based therapies, Wegovy for obesity and ...
Novo Nordisk has one of the broadest diabetes portfolios in the industry. The company continues to be the global market leader in the GLP-1 segment, with around 54% value market share as of the ...